0001209191-22-028277.txt : 20220511 0001209191-22-028277.hdr.sgml : 20220511 20220511161548 ACCESSION NUMBER: 0001209191-22-028277 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220504 FILED AS OF DATE: 20220511 DATE AS OF CHANGE: 20220511 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GAUGLER DARYL CENTRAL INDEX KEY: 0001928278 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 22913905 MAIL ADDRESS: STREET 1: C/O PACIRA BIOSCIENCES, INC. STREET 2: 5 SYLVAN WAY, SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5401 WEST KENNEDY BOULEVARD STREET 2: SUITE 890 CITY: TAMPA STATE: FL ZIP: 33609 BUSINESS PHONE: 813-553-6680 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-05-04 0 0001396814 Pacira BioSciences, Inc. PCRX 0001928278 GAUGLER DARYL C/O PACIRA BIOSCIENCES 5401 WEST KENNEDY BOULEVARD, SUITE 890 TAMPA FL 33609 0 1 0 0 Chief Operating Officer Common Stock 12600 D Stock Option (Right to Buy) 60.96 2031-06-09 Common Stock 15000 D Stock Option (Right to Buy) 52.37 2030-07-02 Common Stock 20000 D Stock Option (Right to Buy) 47.65 2030-06-09 Common Stock 10000 D Stock Option (Right to Buy) 42.54 2029-07-02 Common Stock 20000 D Stock Option (Right to Buy) 34.00 2028-06-04 Common Stock 10000 D Includes 12,000 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 6,000 restricted stock units that vest in four equal annual installments on June 3, 2022, June 3, 2023, June 3, 2024 and June 3, 2025, and (ii) 6,000 restricted stock units that vest in three equal annual installments on June 3, 2022, June 3, 2023 and June 3, 2024, in each case, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. The stock option vested in equal monthly installments over one year following the grant date, provided that the reporting person remained in continuous service with the issuer as of each vesting date. /s/ Kristen Williams, Attorney-in-Fact 2022-05-11 EX-24 2 attachment1.htm EX-24 DOCUMENT

POWER OF ATTORNEY

	I, Daryl Gaugler, hereby authorize and designate each of Charles A. Reinhart,
III, Kristen Williams and Ned Prusse, signing singly, as my true and lawful
attorney-in-fact to:

		(1)	execute for and on my behalf, in my capacity as an officer and/or director
of Pacira BioSciences, Inc. and its affiliates (the "Company"), the Form ID and
Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), and the rules and regulations
promulgated thereunder;

		(2)	do and perform any and all acts for and on my behalf which may be
necessary or desirable to complete and execute any such Form ID or Form 3, 4 or
5 and timely file such form with the Securities and Exchange Commission, any
stock exchange or similar authority; and

		(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney in fact, may be to my benefit,
in my best interest, or legally required of me, it being understood that the
statements executed by such attorney in fact on my behalf pursuant to this Power
of Attorney shall be in such form and shall contain such terms and conditions as
such attorney in fact may approve in such attorney in fact's discretion.

	I hereby further grant to each such attorney in fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as I might or could do if
personally present, with full power of substitutes or revocation, hereby
ratifying and confirming all that such attorney in fact, or such attorney in
fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this Power of Attorney and the rights and powers herein granted.  I
hereby acknowledge that the foregoing attorneys in fact, in serving in such
capacity at my request, are not assuming, nor is the Company assuming, any of my
responsibilities to comply with Section 16 of the Exchange Act.

	This Power of Attorney shall remain in full force and effect until I am no
longer required to file the Form ID or Forms 3, 4 and 5 with respect to my
holdings of and transactions in securities issued by the Company, unless earlier
revoked by me in a signed writing delivered to the foregoing attorneys in fact.

	IN WITNESS WHEREOF, I have caused this Power of Attorney to be duly executed as
of this 3rd day of May, 2022.


	/s/ Daryl Gaugler
	Daryl Gaugler